Wistar announces the opening of its new Center for Advanced Therapeutics (CAT) led by Paul Lieberman, Ph.D., to harness the power of Wistar science and speed creation of new drugs and therapies for h…
New research by Wistar Institute scientists shows how targeting a cleft in the retinoblastoma protein can kill tumor-protecting macrophages in ovarian cancer.
The Wistar Institute announces the appointment of Katherine Aird, Ph.D., as co-leader and professor in the Molecular and Cellular Oncogenesis Program of the Ellen and Ronald Caplan Cancer Center.
The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized “cure regimens” for HIV.
The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious disease, announces the appointment of Simon Chu, Ph.D., as Caspar Wistar Fellow in the Molecular…
PRESS RELEASE CONTACT: Darien Sutton 215-898-3988 | dsutton@wistar.org PHILADELPHIA — (July 10, 2025) — Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs…
Scientists at The Wistar Institute have discovered how a key protein from the Epstein-Barr virus (EBV), EBNA-LP, fundamentally rewires the three-dimensional structure of DNA in infected B cells to pr…
PHILADELPHIA — (May 28, 2025) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Joshua Friedman, M.D., Ph.D., to its B…
PHILADELPHIA — (May 22, 2025) — Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses a…
